Nanobiotix S.A. (NNBXF) SEC Filings

Nanobiotix S.A. (NBTX) reported full Phase 1 cohort results for radiotherapy-activated JNJ-1900 (NBTXR3) in 24 patients with inoperable, locoregionally recurrent non-small cell lung cancer eligible for re-irradiation. All patients completed treatment with no dose-limiting toxicities and no Grade 3 or higher adverse events related to JNJ-1900 or the injection procedure, and intratumoral injection was deemed feasible.

At a median follow-up of 12 months, one-year locoregional control was 79%, one-year local progression-free survival was 61% (median 13.6 months), and one-year overall survival was 70% (median 14.8 months), achieved with re-irradiation doses lower than patients’ prior radiotherapy. Grade 3 radiotherapy-related adverse events occurred in 33% of patients and Grade 5 radiotherapy-related events in 8%. Investigators set the recommended Phase 2 dose at 33% of gross tumor volume and concluded JNJ-1900 (NBTXR3) may support clinically meaningful local control at substantially lower re-irradiation doses, warranting evaluation in a randomized trial and further enrollment.

Nanobiotix S.A. (NBTX), a late-stage clinical biotechnology company, reported that its management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15, 2026 at 12:00 pm EDT / 6:00 pm CEST.

The session will feature Chief Executive Officer Laurent Lévy and Chief Financial and Business Officer Bart Van Rhijn. Nanobiotix highlights its portfolio of more than 30 umbrella patents across three nanotechnology platforms in oncology, bioavailability and biodistribution, and central nervous system disorders.

Nanobiotix S.A. (NBTX) reported its share capital and voting rights position as of July 31, 2026, in line with articles L.233-8 II of the French Commercial Code and article 223-16 of the General Regulation of the French Financial Markets Authority. The company had 50,833,462 shares outstanding. Total theoretical voting rights were 54,534,179, while total exercisable voting rights at shareholder meetings were 54,512,061, reflecting the exclusion of shares with suspended voting rights such as treasury shares. Nanobiotix remains listed on Euronext Paris and the Nasdaq Global Select Market.

Nanobiotix S.A. has an institutional holder group led by Invus Public Equities, L.P. reporting beneficial ownership of 4,483,275 ordinary shares and 345,099 pre-funded warrants, each exercisable for one share at Euro 0.03 per share and expiring May 26, 2036. Based on 50,807,903 shares outstanding as of May 31, 2026, plus the warrant shares, the Invus-related reporting persons each may be deemed to beneficially own 4,828,374 shares, or 9.4% of the company. The group reports sole voting and dispositive power over these securities and certifies that the holdings are not for the purpose of changing or influencing control. Nanobiotix ADSs, each representing one ordinary share, trade under the symbol NBTX and use CUSIP 63009J107.

Nanobiotix S.A. reported its share capital and voting rights position as of June 30, 2026, showing 50,825,682 shares outstanding.

The company reported 54,486,890 theoretical voting rights, used as the basis for calculating threshold crossings, and 54,464,772 exercisable voting rights, which exclude shares held in treasury where voting rights are suspended. Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris and listed on Euronext Paris and the Nasdaq Global Select Market.

Qatar Investment Authority reports beneficial ownership of 3,532,517 Nanobiotix SA Depositary Receipt S ADRs, representing 7.0% of this class. The position carries sole voting and sole dispositive power over all reported ADRs, with no shared voting or dispositive authority.

The ADRs are held through two wholly owned subsidiaries of Qatar Investment Authority: QH Oil Investment LLC, holding 3,304,839 ADRs, and Q Dutis Holding LLC, holding 227,678 ADRs.

Nanobiotix S.A. reports its share capital and voting rights as of May 31, 2026. The company lists 50,807,903 shares outstanding, with total theoretical voting rights of 54,304,858 and total exercisable voting rights of 54,282,740.

Theoretical voting rights include all shares with attached voting rights, even when suspended, and are used to calculate regulatory threshold crossings in France. Exercisable voting rights exclude shares with suspended voting rights, such as treasury shares, to reflect the votes that can actually be cast at a shareholders’ meeting.

Nanobiotix reported its first quarter 2026 update, highlighting stronger funding and progress in its lead oncology programs. The company completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million.

Nanobiotix held €42.1 million in cash and cash equivalents as of March 31, 2026, and believes its financial resources will support operations into 2029. Early Part 1 data from the J&J-sponsored CONVERGE study in unresectable Stage 3 NSCLC showed an overall response rate of 85.7% and complete response rate of 57.1% in 7 patients, with an acceptable safety profile, while a protocol amendment was accepted for the pivotal NANORAY-312 Phase 3 trial.

Nanobiotix S.A. filed a Form 6-K to share that it has been included in the Euronext Tech Leaders segment and added to the Euronext Tech Leaders Index. This Euronext initiative highlights innovative, high-growth European technology companies and aims to increase their visibility with international investors.

The company describes itself as a late-stage clinical biotechnology business pioneering physics-based nanotherapeutic approaches for cancer and other major diseases. Headquartered in Paris and listed on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix owns more than 30 umbrella patents across three nanotechnology platforms in oncology, bioavailability and biodistribution, and central nervous system disorders.